Axsome Therapeutics falls 5.8% after quarterly results on November 2, 2026

What happened

Axsome Therapeutics (AXSM) fell 5.8% on November 2, 2026, after reporting third-quarter results that beat earnings estimates but left investors cautious about the sustainability of recent growth. The stock closed at $136.01 after opening 5.0% below the previous close, and trading volume ran at 2.7 times its 20-day average. The move came in a weaker market: the S&P 500 fell 0.5% while the healthcare sector median fell 1.6%.

How big was the move

The day’s decline was 2.4 times a typical daily move for the stock and was 4.2 percentage points worse than the sector median. Over the last five sessions the stock fell 5.6%, while the S&P 500 over five sessions fell 1.8%. Market sensitivity is moderate, with a beta of 0.90, which indicates the stock tends to move about as much as the market. In the past five years the stock had 47 sessions with a decline of at least 5.8%; twenty trading days later the median result was a gain of 3.2%, and 26 of 47 were higher.

The technical picture

Technically, the stock sat well below its key moving averages, trading 12.7% below its 20-day moving average, 25.8% below its 50-day moving average and 31.7% below its 200-day moving average. The 50-day average is below the 200-day average, a sign of a weak longer-term trend. Momentum measures showed an oversold condition, with a Relative Strength Index (14 days) of 20, below the 30 threshold often called oversold. The share price was 47.7% below the 52-week high after falling 24.1% over one month and 35.9% over three months. Volatility stood at 39% annualized over 60 days, a level lower than 74% of its own readings over five years.

Fundamentals and valuation

For the four quarters through September 30, 2026, Axsome reported revenue of $865.3 million, which grew 54.2% from a year earlier. Gross margin widened to 93.2% from 91.9% a year earlier, while operating margin narrowed to 17.7% from 37.8% a year earlier. Diluted earnings per share for the period were $-3.06 and free-cash-flow margin was 9.5%. Return on invested capital stood at 50.7%, and the balance sheet held net cash of $95.2 million. Share count over one year increased by 4.8%.

On valuation, free-cash-flow yield was 1.1%. PromtFinance scores within the sector highlighted strong Growth at 86 and strong Stability at 83, with Momentum at 31 (Weak) and Quality at 50 (Neutral). Those scores portray a company with rapid top-line expansion and a solid balance sheet but weakening near-term momentum and profitability metrics versus the immediate prior year.

Earnings and analyst expectations

Axsome reported on November 2, 2026, earnings per share of $-0.25 against $-0.63 expected, 60.6% above estimates, marking one consecutive quarter beating estimates. The company reported total net product revenue of $259.7 million, driven mainly by AUVELITY sales of $207.6 million, SUNOSI at $48.2 million and SYMBRAVO at $3.9 million. Those product figures represent year-over-year increases of 53% for AUVELITY, 47% for SUNOSI and 88% for SYMBRAVO.

Management discussed ongoing commercial expansion of AUVELITY in major depressive disorder and Alzheimer’s disease agitation during the earnings call. Outside commentary flagged that AUVELITY’s ADA launch is progressing more slowly than some had expected and that recent quarter growth included one-time items and improved gross-to-net rather than purely sustainable volume increases. The company’s typical two-day reaction after recent reports was to rise 0.9%.

Analyst coverage remained heavily positive. Twenty-seven analysts follow the stock, producing a consensus rating of Buy and a consensus price target of $281.67, which is 107.1% above the closing price. Ninety-six percent of analysts rate the stock Buy or Strong Buy. The next report is scheduled for February 22, 2027.

What to watch

• November 2, 2026: third-quarter results — earnings per share of $-0.25 against $-0.63 expected, 60.6% above estimates, and total net product revenue of $259.7 million
• Management commentary on AUVELITY commercial expansion in major depressive disorder and Alzheimer’s disease agitation from the earnings call
• Analyst coverage: consensus price target of $281.67 and 96% of analysts rate the stock Buy or Strong Buy
• February 22, 2027: next scheduled earnings report
• Trading and technical signals: Relative Strength Index (14 days) at 20 and trading 31.7% below its 200-day moving average